|

Breaking: US will have effective Covid-19 vaccine by year-end – Fauci

Reuters reports that the leading US expert on infectious diseases, Dr. Anthony Fauci, predicted on Wednesday the country will meet its goal of a coronavirus vaccine by year's end and was unmoved by the prospect that China would get there first.

While there are no guarantees,

I feel good about the projected timetable,

Fauci told Reuters in an interview.

His comments follow promising early-stage data for the Moderna Inc's coronavirus vaccine, released on Tuesday, that was developed by scientists at the National Institute of Allergy and Infectious Diseases, which Fauci directs. 

Key notes

  • Infectious disease expert Fauci tells Reuters that u.s. will have effective coronavirus vaccine by year-end.
  • Fauci tells Reuters that Moderna's vaccine trial results were especially promising.
  • Fauci tells Reuters he does not think China will be first with a vaccine, at least not by much.

Fauci also said Moderna's results were especially promising because the vaccine appeared to offer the type of protection seen in a natural infection.

One of the things that you hope for is that your vaccine induces a response that's comparable to a natural infection, because theoretically, the best vaccine you could possibly ever get is a natural infection.

Reuters explained that "Moderna's candidate, which is set to enter the last stage of testing on July 27, is just one of more than a hundred vaccines in development globally, but only one of a few contenders that have earned millions of dollars in backing from Operation Warp Speed, the White House program that aims to deliver more than 300 million doses of a safe and effective COVID-19 vaccine by January."

Market implications

The market reaction to these comments from Fauci was muted considering the news dropped yesterday that there are promising signs with the vaccine following results of the test on 45 volunteers which revved-up and improved their immune systems.

Many experts see a safe and effective vaccine as the only way out of the pandemic that has infected millions and killed more than 575,000 people worldwide.

However, the statements made today should cement the improved risk-on themes in markets as we run into key economic data released today from China and ahead of US Retail Sales and the European Central Bank, likely playing second fiddle, however, to the EU summit this weekend. 

Inflation pressures will be the theme fs the vaccine rubber hits the road, a topic discussed in the following usual suspects earlier today:

Gold prices march-on above a key support structure as inflation expectations ramp-up

DXY meeting resistance in a bullish correction, bears lurking on risk-on themes gaining traction

Update from after the bell:

Author

More from FXStreet Team
Share:

Markets move fast. We move first.

Orange Juice Newsletter brings you expert driven insights - not headlines. Every day on your inbox.

By subscribing you agree to our Terms and conditions.

Editor's Picks

EUR/USD rebounds after falling toward 1.1700

EUR/USD gains traction and trades above 1.1730 in the American session, looking to end the week virtually unchanged. The bullish opening in Wall Street makes it difficult for the US Dollar to preserve its recovery momentum and helps the pair rebound heading into the weekend.

GBP/USD steadies below 1.3400 as traders assess BoE policy outlook

Following Thursday's volatile session, GBP/USD moves sideways below 1.3400 on Friday. Investors reassess the Bank of England's policy oıtlook after the MPC decided to cut the interest rate by 25 bps by a slim margin. Meanwhile, the improving risk mood helps the pair hold its ground.

Gold stays below $4,350, looks to post small weekly gains

Gold struggles to gather recovery momentum and stays below $4,350 in the second half of the day on Friday, as the benchmark 10-year US Treasury bond yield edges higher. Nevertheless, the precious metal remains on track to end the week with modest gains as markets gear up for the holiday season.

Crypto Today: Bitcoin, Ethereum, XRP rebound amid bearish market conditions

Bitcoin (BTC) is edging higher, trading above $88,000 at the time of writing on Monday. Altcoins, including Ethereum (ETH) and Ripple (XRP), are following in BTC’s footsteps, experiencing relief rebounds following a volatile week.

How much can one month of soft inflation change the Fed’s mind?

One month of softer inflation data is rarely enough to shift Federal Reserve policy on its own, but in a market highly sensitive to every data point, even a single reading can reshape expectations. November’s inflation report offered a welcome sign of cooling price pressures. 

XRP rebounds amid ETF inflows and declining retail demand demand

XRP rebounds as bulls target a short-term breakout above $2.00 on Friday. XRP ETFs record the highest inflow since December 8, signaling growing institutional appetite.